PolyPid: Strong Phase 3 Data Support A Buy Ahead Of November's FDA Decision (NASDAQ:PYPD)
· seekingalpha.com
PolyPid's SHIELD II Phase 3 data showed clinically meaningful reductions in surgical site infections. Read why I rate PYPD stock a Buy.
Eljaye W. Tellis is a medicinal chemistry Ph.D. candidate and biotech investor. He covers biotechnology and healthcare equities, applying a therapeutic discover...